CDK5 and medullary thyroid gland carcinoma: In human MTC, oncogenic signaling, frequently driven by gain-of-function mutations in the RET receptor tyrosine kinase, leads to the overexpression of the Cdk5 activator p35 and subsequent Cdk5 hyperactivation.